Acute Myeloid Leukemia
Pipeline by Development Stage
Drug Modality Breakdown
Acute Myeloid Leukemia is a ~$1.3B Part D market with mature, peak-stage dominance by targeted small molecules and consolidating competitive dynamics.
Key Trends
- IDH inhibitors and FLT3 inhibitors dominate; one P-glycoprotein inhibitor accounts for ~65% of MoA spend
- Patent cliff risk materializing: ONUREG ($69M) loses exclusivity June 2030; SYNRIBO expires October 2026
- Phase 1/2 trial activity high (438 trials combined), signaling continued innovation in combination strategies and resistance mechanisms
Career Verdict
AML is a stable, specialty-focused oncology niche with solid hiring at large caps (AbbVie, BMS, Takeda) but limited growth upside; best suited for candidates seeking specialized medical affairs, clinical operations, or R&D roles rather than rapid advancement.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | MAVENCLAD (cladribine) | Fresenius Kabi | $156M | 12% | PEAK | Stable | 15.4yr |
| 2 | IDHIFA (enasidenib mesylate) | Bristol Myers Squibb | $119M | 9% | PEAK | Stable | 8.4yr |
| 3 | XOSPATA (gilteritinib) | Astellas | $90M | 7% | PEAK | Stable | 10.2yr |
| 4 | ONUREG (azacitidine) | Bristol Myers Squibb | $69M | 5% | PEAK | Declining | 4.1yr |
| 5 | REZLIDHIA (olutasidenib) | Rigel Pharmaceuticals | $7M | 0.5% | PEAK | Stable | 13.5yr |
Drug Class Breakdown
dominant but undifferentiated
heterogeneous innovation
niche, mature
patent cliff approaching
minimal uptake
Career Outlook
StableAML is a mature, specialty-focused market with predictable revenue streams and consolidated competition; career growth is measured rather than explosive. Hiring is steady at large-cap pharma (especially in medical affairs, clinical ops, and commercial) but limited at smaller biotechs and generics players. Most opportunity lies in supporting existing blockbusters (IDH/FLT3 inhibitors) through payer negotiations, real-world evidence, and resistance-management strategies rather than driving novel launches.
Breaking In
Entry-level candidates should target Clinical Ops, HEOR analyst, or Commercial Intelligence roles at AbbVie, BMS, or Takeda to build specialty oncology credibility; pursue certifications in health economics or clinical trial management to differentiate.
For Experienced Professionals
Seasoned professionals (8+ years) should pivot toward Medical Affairs leadership or Market Access Director roles to command $250K+ compensation; AML's consolidation and patent-cliff exposure create openings in portfolio rationalization and pipeline succession planning.
In-Demand Skills
Best For
Hiring Landscape
AML hiring concentrates in Commercial (1,192 roles, $255K avg), Medical Affairs (264 roles, $302K avg), and Clinical Operations (259 roles, $307K avg), reflecting a mature market prioritizing access and outcomes management over new product launches. Large pharma (AbbVie, J&J, Takeda, AstraZeneca, Roche) dominate headcount; smaller specialists (Rigel, Daiichi) rarely recruit. Manufacturing and engineering roles (489 and 447 respectively) signal continued manufacturing optimization and process scale-up.
Top Hiring Companies
By Department
Strong headcount at marquee pharma companies, but growth is incremental; Medical Affairs and Clinical Operations offer highest compensation and most stable advancement paths.
On Market (3)
Approved therapies currently available
Competitive Landscape
148 companies ranked by most advanced pipeline stage
+118 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 10,534 patients across 50 trials
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML
A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia
Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia
Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Prevention of Left Ventricular Dysfunction During Chemotherapy
Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk
Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia
A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)
Trial of Decitabine in Patients With Acute Myeloid Leukemia
Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide
To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning
Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission
FLT3-ITD Targeted Therapy in Fit AML Patients
Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients
Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing Chemotherapy
Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia
Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.
Motixafortide for MRD Sensitization in AML
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
Related Jobs in Oncology
Facilities & Lab Coordinator
Executive Director, Global Clinical Development, Early Hematology and Cell Therapy
Associate Director, Clinical Scientist, Genetics Medicine
Senior Director, Medical & Regulatory Writing
Cell Therapy Account Manager, Raleigh/Durham
Senior Director, Pharmacovigilance (Safety Science & Surveillance)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.